Market Overview

UPDATE: MLV & Co Downgrades Uroplasty to Hold on Slowing Growth, Competitive Concerns

Related UPI
Morning Market Movers
Morning Market Movers

MLV & Co downgraded Uroplasty (NASDAQ: UPI) from Buy to Hold and announced a $3.00 price target.

MLV & Co noted, "Given our expectations for low growth over the next year and the recent approval of two competitive products for OAB from companies with much greater marketing prowess (and budgets) than Uroplasty, we no longer have sufficient visibility to project when the company may reach profitability. Further, we believe lessthan-positive market sentiment and a lack of any meaningful nearterm catalysts will continue to weigh heavily on the shares."

Uroplasty closed at $2.74 on Monday.

Latest Ratings for UPI

DateFirmActionFromTo
Jan 2014Dougherty & CompanyReinstatesBuy
May 2013JMP SecuritiesUpgradesMarket PerformMarket Outperform
Jan 2013MLV & Co.DowngradesBuyHold

View More Analyst Ratings for UPI
View the Latest Analyst Ratings

Posted-In: MLV & CoAnalyst Color Downgrades Analyst Ratings

 

Related Articles (UPI)

Around the Web, We're Loving...

Get Benzinga's Newsletters